325
Participants
Start Date
November 6, 2015
Primary Completion Date
July 6, 2016
Study Completion Date
July 6, 2016
Batefenterol
Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister
Umeclidinium/ Vilanterol
Umeclidinium/Vilanterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain umeclidinium blended with lactose and magnesium stearate with a unit dose strength of 62.5 mcg per blister and the second strip will contain vilanterol blended with lactose and magnesium stearate with a unit dose strength of 25 mcg per blister
Placebo
Placebo will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip) containing lactose
GSK Investigational Site, Meyerspark/ Pretoria
GSK Investigational Site, Middelburg
GSK Investigational Site, Port Elizabeth
GSK Investigational Site, Somerset West
GSK Investigational Site, Bellville
GSK Investigational Site, Mowbray
GSK Investigational Site, Bloemfontein
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Rüdersdorf
GSK Investigational Site, Baltimore
GSK Investigational Site, Hamburg
GSK Investigational Site, Großhansdorf
GSK Investigational Site, Lübeck
GSK Investigational Site, Spartanburg
GSK Investigational Site, Union
GSK Investigational Site, Greenville
GSK Investigational Site, Anderson
GSK Investigational Site, Simpsonville
GSK Investigational Site, Hialeah
GSK Investigational Site, Wiesbaden
GSK Investigational Site, Medford
GSK Investigational Site, St Louis
GSK Investigational Site, Thabazimbi
Lead Sponsor
GlaxoSmithKline
INDUSTRY